Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Using the continual reassessment method: lessons learned from an EORTC phase I dose finding study.

Xavier Paoletti1, Benoît Baron, Patrick Schöffski

  • 1Inserm, U738, F-75018 Paris, France. x.paoletti@institutcancer.fr

European Journal of Cancer (Oxford, England : 1990)
|June 3, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors.

Nature cancer·2026
Same author

Predicting clinical sensitivities of PDGFRA exon 18 mutations to imatinib and avapritinib to optimize gastrointestinal stromal tumor treatment.

Cancer research communications·2026
Same author

Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Leveraging the potential of prospective registries for radiation oncology research: 5-year experience from the EORTC-ESTRO radiotherapy infrastructure for Europe (E<sup>2</sup>-RADIatE) project.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Pragmatism in academic gastrointestinal cancer clinical trials: An analysis of trials conducted by the EORTC gastrointestinal tract cancer group and the unicancer gastrointestinal group.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Academic clinical cancer trials to improve patient outcomes.

The Lancet. Oncology·2026
Same journal

Early-onset colorectal cancer across Europe: Burden, mechanisms, and health-system implications.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinical urgency of incidental findings in the first year of the 4-IN-THE-LUNG-RUN lung cancer screening program.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Left behind but not left alone: Excluded cell populations in the non-small cell lung cancer stroma predict superior long-term overall survival.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS).

European journal of cancer (Oxford, England : 1990)·2026
See all related articles

The Continual Reassessment Method (CRM) offers an accurate way to estimate the maximum tolerated dose (MTD) in Phase I clinical trials. While effective, careful consideration of dose-limiting toxicity is crucial for successful implementation.

Area of Science:

  • Clinical Pharmacology
  • Biostatistics
  • Oncology Drug Development

Background:

  • The Continual Reassessment Method (CRM) is an alternative dose-escalation schema for Phase I clinical trials.
  • Clinician comfort and understanding of CRM can be a barrier to its widespread adoption.
  • The classical 'Fibonacci' schema is the traditional method for dose escalation.

Purpose of the Study:

  • To review the implementation, characteristics, advantages, and limitations of CRM in Phase I studies.
  • To present a case study of a two-center, dose-escalation Phase I study using CRM.
  • To illustrate management issues in multicenter studies and potential pitfalls of CRM.

Main Methods:

  • Review of CRM principles and comparison with the Fibonacci schema.

Related Experiment Videos

  • Implementation of a 2-step CRM design in a Phase I dose-escalation study of rViscumin.
  • Analysis of patient data (n=37) across 14 dose levels (10 to 6400 ng/kg).

    • Main Results:

    • A 2-step CRM design can accelerate Phase I studies and accurately estimate the maximum tolerated dose (MTD).
    • Management issues in multicenter trials were illustrated.
    • Failure to adequately consider dose-limiting toxicity (DLT) can compromise CRM effectiveness.

    Conclusions:

    • CRM is a statistically and practically sound alternative to standard dose-finding methods for Phase I trials.
    • Further methodological research is needed to address the composite nature of toxicity endpoints in CRM.
    • Successful CRM implementation requires careful clinician consideration of dose-limiting toxicities.